Collaboration for wound care treatment
Lyon, Cleveland, June 27th, 2017 - AMOEBA announced today the development of a collaboration with VISCUS BIOLOGICS in order to carry out collective testing on a new wound care application in the field of human health.
VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in particular collagen-based dressings. Following preliminary in vitro testing, the two companies intend to extend their cooperation and further confirm, through additional in vitro and in vivo testing, the action of the Willaertia magna C2c Maky micro-organism against certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple antibiotics. Willaertia magna C2c Maky could therefore be used with advanced wound care dressings. This project is in the first instance focusing on the US market.